Athersys (ATHX) Q3 2019 Earnings Call Transcript
ATHX earnings call for the period ending September 30, 2019.
Athersys
ATHX
ATHX
$1.33
$0.03
2.3%
BATS BZX Real Time Price as of December 6, 2019, 4:00 p.m. EST
View Interactive ATHX Charts
Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.
News & Analysis: Athersys
Athersys (ATHX) Q2 2019 Earnings Call Transcript
ATHX earnings call for the period ending June 30, 2019.
Here's Why Athersys Rose as Much as 15.2% Today
The FDA has given the company's lead drug platform a potential leg up in development.
Athersys (ATHX) Q1 2019 Earnings Call Transcript
ATHX earnings call for the period ending March 31, 2019.
Here's Why Athersys Is Soaring Today
The stem cell pioneer announced an update with its most important collaborator.
Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript
ATHX earnings call for the period ending December 31, 2019.
Here's What Might Be Pushing Up Shares of Athersys, Inc. Today
An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.
3 Stocks That Have Doubled in 2016 Alone
But beware: Not all that glitters is gold.
Why Athersys, Inc. Shares Are Soaring Higher Today
Athersys, Inc. will present phase 2 data for its stem cell therapy as a treatment for ischemic stroke on April 19th.
The Biggest Biotech Catastrophes of the Week
See which companies suffered the worst clinical setbacks in the week ending May 2.
